ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes
Anja Soldan, Corinne Pettigrew, Anne M Fagan, Suzanne E Schindler, Abhay Moghekar, Christopher Fowler, Qiao-Xin Li, Steven J Collins, Cynthia Carlsson, Sanjay Asthana, Colin L Masters, Sterling Johnson, John C Morris, Marilyn Albert, Alden L Gross
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019
OBJECTIVE: To examine the long-term cognitive trajectories of individuals with normal cognition at baseline and distinct amyloid/tau/neurodegeneration (ATN) profiles. METHODS: Pooling data across 4 cohort studies, 814 cognitively normal participants (mean baseline age = 59.6 years) were classified into 8 ATN groups using baseline CSF levels of β-amyloid 1-42 as a measure of amyloid (A), phosphorylated tau 181 as a measure of tau (T), and total tau as a measure of neurodegeneration (N). Cognitive performance was measured using a previously validated global factor score and with the Mini-Mental State Examination. We compared the cognitive trajectories across groups using growth curve models (m..View full abstract
Awarded by National Institute on Aging
Awarded by NATIONAL INSTITUTE ON AGING
The Preclinical AD Consortium is supported by the Alzheimer's Association and Fidelity Biosciences. The individual studies in the consortium are funded, in part, by the following grants: U19-AG03365, P01-AG026276, R01-AG027161, and the Australian Commonwealth Scientific Industrial Research Organization (CSIRO). Dr. Gross is supported by K01AG050699 from the National Institute on Aging.